The Oxford vaccine — which the UK government has pre-ordered 100 million doses of — has shown a 70% efficacy rate following a large scale trial.
Meanwhile, American biotech and pharmaceutical companies Pfizer and BioNTech showed 90-95% protection following their vaccine trials.
If approved by regulators, the Oxford vaccine can still play a crucial role in controlling the pandemic as it is cheaper and easier to produce compared to Pfizer and BioNTech.
The UK has also placed 40 million orders for the Pfizer and BioNTeach vaccines.
According to the BBC, there is data that suggests perfecting the Oxford vaccine dose could increase protection up to 90%.
Andrew Pollard, head of Oxford Vaccine Group told BBC Radio 4: “We’re really pleased with these results,”
“What we’ve got is a vaccine that is able to protect against coronavirus disease and importantly there were no hospitalisations or severe cases in anyone who had the Oxford vaccine”
“That means that if we did have people vaccinated – so far the results imply that we’d be able to stop people getting severe diseasing, going into hospital.”
Health secretary Matt Hancock tweeted that the result was “very encouraging news” and that although it was “not there yet”, good progress is being made.
Prime Minister Boris Johnson added that despite the ‘fantastic results’, there are still further safety checks needed ahead.
Words: Zakia Nissar | Subbing: Warshma Chughtai